Contribute Try STAT+ Today

Editor’s note: A recording of the conversation is embedded below.

Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma, and health tech leaders. This week, STAT senior medicine writer and editorial director of events Matthew Herper and STAT general assignment reporter Kate Sheridan sit down to discuss the second edition of her report “Ranking biotech’s top venture capital firms.”  They will explore which venture capital funds performed best during the pandemic, and of course be taking your questions live.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment